Form 4: Enliven Therapeutics Director Jake Bauer Acquires Stock Options
SEC Form 4 Filing
Director Jake Bauer of Enliven Therapeutics acquired stock options exercisable for 20,491 shares of common stock.
Summary
- On February 6, 2025, Jake Bauer, a director of Enliven Therapeutics, Inc., acquired stock options representing the right to buy 20,491 shares of common stock at an exercise price of $22.47.
- The options vest on the earlier of the first anniversary of the 2025 annual meeting or the date of the 2026 annual meeting, contingent upon continued service as a non-employee director.
- Following the transaction, Bauer directly owns 20,491 derivative securities (stock options).
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing an insider transaction. It doesn't inherently convey positive or negative sentiment about the company's prospects.
Future Outlook
The document does not contain specific forward-looking statements regarding the company's future performance, but the vesting of the options is contingent on continued service as a non-employee director.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions, providing transparency to investors regarding the holdings and transactions of company directors. It is common for directors to receive stock options as part of their compensation.
Stakeholder Impact
- The transaction provides transparency to shareholders regarding director compensation and alignment of interests.
Key Dates
| Date | Description |
|---|---|
| 02/06/2025 | Date of stock option grant |
| 02/06/2025 | Transaction Date |
| 02/10/2025 | Date of Form 4 filing |
| 02/06/2035 | Expiration date of the stock options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.